[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"uncontrolled-hypertension\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:uncontrolled-hypertension":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,14,0,[8,48,76,108,136,160,185,218,241,263,288,308,333,358],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100603887","phase-2-a-study-of-modified-release-rtn-001-in-patients-with-uncontrolled-hypertension-100603887",false,"NCT07142356","A Study of Modified Release RTN-001 In Patients With Uncontrolled Hypertension","A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multicenter Study of Modified Release RTN-001 In Patients With Uncontrolled Hypertension","Inclusion Criteria:\n\n1. Provision of written informed consent before any study-specific procedure.\n2. Male or female patients age 18 to 70 years, inclusive, at the Screening Visit.\n3. Uncontrolled HTN despite being on a stable regimen of ≥ 2 antihypertensive medications in the following drug classes: ACE-inhibitors, ARBs, beta blockers, calcium channel blockers, mineralocorticoid receptor antagonists, or diuretics. A stable regimen is defined as being on the same medications and the same dose for at least 30 days before screening. A combination pill containing 2 separate classes of antihypertensive drugs is considered 2 antihypertensive medications.\n4. Mean BP of ≥ 130\u002F80 mm Hga.\n5. Men and nonpregnant, nonlactating women. Women must be either:\n\n   * Naturally postmenopausal defined as ≥ 1 year without menses and follicle-stimulating hormone ≥ 40.0 IU\u002FL, or\n   * Surgically sterile including hysterectomy, bilateral oophorectomy, and\u002For tubal ligation, or\n\n   Women of childbearing potential must be willing to use 2 acceptable methods of birth control (unless they have agreed to follow the definition of true abstinence). The minimal requirement for adequate contraception should be started the day of Visit T1 (Day 1), continuing during the Treatment Period and for at least 30 days after the last dose of study drug. Acceptable methods of birth control include:\n   * Oral, implantable, injectable, or topical birth control medications. Note: Oral birth control medication must be started ≥ 30 days before the first dose of treatment in the Placebo Run-in.\n   * Placement of an intrauterine device with or without hormones.\n   * Barrier methods including condom or occlusive cap with spermicidal foam or spermicidal jelly.\n   * Vasectomized male partner who is the sole partner for this patient.\n   * True abstinence when this is the preferred and usual lifestyle of the patient. Periodic abstinence (eg, calendar, ovulation, symptothermal, postovulation methods), declaration of abstinence for the duration of a trial, and withdrawal are not acceptable methods of contraception.\n6. Body mass index of 18 to 35 kg\u002Fm2.\n7. Negative prestudy urine drugs of abuse screen (with the exception of tetrahydrocannabinol \\[THC\\]).\n8. If taking a PDE5 inhibitor for erectile dysfunction, must be willing to pause use during the study period.\n\nOnly patients with uncontrolled HTN on ≥ 2 accepted classes of antihypertensive drugs who continue to satisfy the inclusion criteria above, are \\> 80% compliant during the Placebo Run-in dosing of 3 tablets QD of single-blind placebo and have successfully completed the baseline 24 hour ABPM will be randomly assigned to treatment with RTN-001 or matching placebo.\n\naThe initial BP inclusion criterion will be ≥ 130\u002F80 mm Hg. After approximately 25% of patients (80 patients) have been randomly assigned to study treatment, the actual baseline BP of randomized patients will be reviewed to ensure target distribution of BP at study entry. If the mean baseline SBP is not within the target range of approximately 145 mm Hg, the inclusion criterion may be modified to reflect a higher BP inclusion criterion.\n\nExclusion Criteria:\n\n1. Currently enrolled in a study with an investigational product or any other type of medical research within 30 days before randomization.\n2. Mean seated SBP \\> 170 mm Hg and\u002For DBP \\> 110 mm Hg.\n3. Current or planned use of nitrates and\u002For alpha-blockers or other drugs known to affect BP during the study period (except for those allowed in the protocol; Section 5.9.2) including SGLT2 inhibitors and GLP-1 agonists.\n4. Regular user of PDE5 inhibitors or cannot\u002Fis unwilling to refrain from use of PDE5 inhibitors for 7 days before and during their participation in the study.\n5. History of hypotension, fainting spells, or blackouts, including orthostatic hypotension.\n6. Malignant HTN, primary aldosteronism, or secondary HTN.\n7. Active pancreatitis.\n8. A history of drug abuse.\n9. Abuses alcohol defined as average weekly intake greater than 21 units for males or 14 units for females. One unit is equivalent to a 12 oz beer, 1 measure of spirits, or 1 glass of wine.\n10. History or presence of gastrointestinal, hepatic, or renal disease or other conditions that would be known to interfere with the absorption, distribution, metabolism, or excretion of drugs.\n11. Recent (within 3 months before the Screening Visit \\[Visit S1\\]) myocardial infarction; unstable angina leading to hospitalization; uncontrolled, symptomatic cardiac arrhythmia (or medication for an arrhythmia that was started or dose changed within 3 months of screening); coronary artery bypass graft; percutaneous coronary intervention; carotid surgery or stenting; cerebrovascular accident; transient ischemic attack; endovascular procedure or surgical intervention for peripheral vascular disease; or plans to undergo a major surgical or interventional procedure (eg, percutaneous coronary intervention, coronary artery bypass graft, carotid or peripheral revascularization). Patients with implantable pacemakers or automatic implantable cardioverter defibrillators may be considered if deemed by the Investigator to be stable for the previous 3 months.\n12. Uncontrolled hypothyroidism, including thyroid-stimulating hormone \\> 1.5 × the upper limit of normal (ULN) at the Screening Visit (Visit S1); patients stabilized on thyroid replacement therapy for at least 6 weeks before randomization are allowed.\n13. Liver disease or dysfunction, including:\n\n    1. Positive serology for hepatitis B surface antigen and\u002For hepatitis C antibodies at the Screening Visit (Visit S1), or\n    2. Alanine aminotransferase (ALT), aspartate aminotransferase (AST) ≥ 2 × ULN, and\u002For total bilirubin (TB) ≥ 2 × ULN at the Screening Visit (Visit S1). If TB ≥ 1.2 × ULN, a reflex indirect (unconjugated) bilirubin will be obtained, and if consistent with Gilbert's syndrome or if the patient has a history of Gilbert's syndrome, the patient may be enrolled in the study.\n\n    Note: At the discretion of the Investigator, a repeat of ALT and\u002For AST may be completed before randomization. For those patients who have a repeat ALT and\u002For AST, the repeat value will be used to determine eligibility. Also, if the patient tests positive for the hepatitis C antibody, but the optional reflexive test for hepatitis C RNA is negative, the patient can be enrolled.\n14. Renal dysfunction or glomerulonephritis, including estimated glomerular filtration rate (eGFR) by Chronic Kidney Disease-Epidemiology Collaboration (CKD-EPI) formula \\\u003C 45 mL\u002Fmin\u002F1.73 m2 at the Screening Visit (Visit S1). Note: a single repeat qualifying eGFR, performed at the discretion of the Investigator, is acceptable.\n15. Gastrointestinal conditions or procedures (including weight loss surgery \\[eg, Lap-Band or gastric bypass\\] that may affect drug absorption.\n16. Hematologic or coagulation disorders or a hemoglobin level \\\u003C 10.0 g\u002FdL at the Screening Visit (Visit S1).\n17. Active malignancy, including a malignancy requiring surgery, chemotherapy, and\u002For radiation in the 5 years before Screening. Nonmetastatic basal or squamous cell carcinoma of the skin and cervical carcinoma in situ are allowed.\n18. Unexplained creatine kinase (CK) \\> 3 × ULN at any time before randomization, which is not associated with recent trauma or physically strenuous activity. Patients with an explained CK elevation must have a single repeat CK ≤ 3 × ULN before randomization.\n19. Blood donation, participation in multiple blood draws, clinical study, major trauma, blood transfusion, or surgery with or without blood loss within 30 days before randomization.\n20. Use of any experimental or investigational drug(s) within 30 days before Screening.\n21. An employee or contractor of the facility conducting the study, or a family member of the principal investigator, co-investigator, or any Sponsor personnel\n22. Is considered to be unsuitable for any other reason that may either place the patient at increased risk during participation or interfere with the interpretation of study outcomes by the Investigator, after reviewing the medical and psychiatric history, physical examination, and laboratory evaluation.","ALL","18 Years","70 Years",{"count":20,"type":21},280,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","The goal of this clinical trial is to learn if the drug RT-001 works to reduce high blood pressure (hypertension) in adults. It will also learn about the safety of RTN-001. The main questions it aims to answer are:\n\nDoes RTN-001 lower blood pressure in patients who have uncontrolled hypertension? What medical problems do participants have when taking RTN-001?\n\nResearchers will compare RTN-001 to a placebo (a look-alike substance that contains no drug) to see if RTN-001 works to treat uncontrolled hypertension.\n\nParticipants will:\n\nTake RTN-001 or a placebo every day for 12 weeks Visit the clinic about once every 2 weeks for checkups and tests Keep a diary of their symptoms and all medications that they take including RTN-001",[27],"Uncontrolled Hypertension",[29,30,31,32,33,34],"hypertension","uncontrolled hypertension","RTN-001","blood pressure","systolic","diastolic","RECRUITING","2026-06-26",{"date":38,"type":39},"2026-06-29","ACTUAL",{"date":41,"type":39},"2025-10-31",{"date":43,"type":21},"2027-05",{"name":45,"class":46},"Retension Pharmaceuticals. Inc.","INDUSTRY",22,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":22,"phases":58,"briefSummary":59,"conditions":60,"keywords":61,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":75},"100641323","phase-2-a-phase-ii-clinical-trial-of-efficacy-and-safety-of-sal0140-at-different-doses-in-patients-with-uncontrolled-hypertension-100641323","NCT07654140","A Phase II Clinical Trial of Efficacy and Safety of SAL0140 at Different Doses in Patients With Uncontrolled Hypertension","A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial of Efficacy and Safety of SAL0140 at Different Doses in Patients With Uncontrolled Hypertension","Inclusion Criteria:\n\n1. Patients 18-75 years old, male or female.\n2. Mean seated systolic blood pressure (msSBP) at screening was ≥140 mmHg and \\\u003C180 mmHg.\n3. Meet either item A or B at screening: A. Uncontrolled hypertension (uHTN); B. Resistant hypertension (rHTN).\n4. Mean seated systolic blood pressure (msSBP) prior to randomization was ≥140 mmHg and \\\u003C180 mmHg.\n5. Voluntarily participate in this study and sign the informed consent form.\n6. Agree to comply with contraception and fertility restrictions of this study.\n\nExclusion Criteria:\n\n1. Severe hypertension (msSBP ≥ 180 mmHg and\u002For msDBP ≥ 110 mmHg); malignant hypertension, hypertensive emergency, hypertensive crisis, hypertensive encephalopathy, etc.\n2. Compliance with study drug during the run-in period was less than 80% or greater than 120%.\n3. Hypertension complicated with the following conditions: acute coronary syndrome, myocardial infarction, percutaneous coronary intervention, stroke.\n4. Positive results for any of human immunodeficiency virus antibody (HIV), hepatitis C virus antibody (HCV), treponema pallidum antibody (TP); or positive hepatitis B surface antigen (HBsAg) with HBVDNA ≥ 1000 IU\u002FmL.\n5. Patients with active malignant tumors.\n6. Patients receiving hemodialysis or adhering to strict salt restriction therapy.\n7. History of adrenal insufficiency.\n8. History of solid organ or bone marrow transplantation.\n9. Gastrointestinal diseases or post-gastrointestinal surgery.\n10. Known or suspected hypersensitivity to aldosterone synthase inhibitors; known or suspected contraindications or hypersensitivity to background medications.\n11. History of drug abuse or alcohol abuse.\n12. Blood donation or significant blood loss.","75 Years",{"count":57,"type":21},252,[24],"This is a multicenter, randomized, double-blind, placebo-controlled phase II study designed to explore the efficacy and safety of different doses of SAL0140 in uncontrolled hypertension.",[27],[62,63,64,65],"Hypertension","Aldosterone Synthase Inhibitor","Renin","Angiotensin","2026-06-12",{"date":68,"type":39},"2026-06-17",{"date":70,"type":39},"2025-12-09",{"date":72,"type":21},"2027-07-31",{"name":74,"class":46},"Shenzhen Salubris Pharmaceuticals Co., Ltd.",1,{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":83,"sex":16,"minAge":17,"maxAge":84,"enrollmentInfo":85,"targetDuration":4,"studyType":22,"phases":87,"briefSummary":89,"conditions":90,"keywords":93,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":75},"100562998","wearable-evaluation-of-ambulatory-readings-for-blood-pressure-100562998","NCT06610448","Wearable Evaluation of Ambulatory Readings for Blood Pressure","WEAR-BP","Inclusion Criteria:\n\n* Age 18 to 100 years\n* All neighborhoods in Boston area\n* Be able to walk with two limbs and have two arms\n* Willing and able to complete required measurement procedures\n* Able to provide informed consent\n\nExclusion Criteria:\n\n* Failure to receive informed consent\n* Arm circumference of more than 50cm",true,"100 Years",{"count":86,"type":21},100,[88],"NA","The purpose of this project is to compare the performance and validity of novel wearable technologies that measure blood pressure (BP) and physical activity with a Spacelabs Ambulatory Blood Pressure Monitoring (ABPM) device.",[91,92,27],"Normal Blood Pressure","Controlled Hypertension",[94,95,96,97,62],"Cuff-based BP device","Cuffless BP device","ABPM","Blood Pressure","2026-06-09",{"date":100,"type":39},"2026-06-11",{"date":102,"type":39},"2025-06-06",{"date":104,"type":21},"2027-07-01",{"name":106,"class":107},"Stephen Juraschek","OTHER",{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":114,"eligibilityCriteria":115,"healthyVolunteers":11,"sex":16,"minAge":116,"maxAge":117,"enrollmentInfo":118,"targetDuration":4,"studyType":22,"phases":120,"briefSummary":121,"conditions":122,"keywords":123,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":75},"100556645","remote-hypertension-management-for-black-patients-100556645","NCT06527794","Remote Hypertension Management for Black Patients","Remote Hypertension Tracking, Help, and Management to Reduce Disparities in Black Patients","RHYTHM-B","Inclusion Criteria:\n\n* Black or African American race\n* Hypertension diagnosis\n* aged 21 to 85 years\n* Uncontrolled blood pressure as defined by \\[a\\] most recent SBP ≥140 mmHg and an additional SBP≥140 mmHg within the past 12 months in an outpatient setting (excluding urgent care, emergency department or surgery clinic), or \\[b\\] most recent SBP\\>160mmHg in an outpatient setting (excluding urgent care, emergency department or surgery clinic), or \\[c\\] referral by PCP for uncontrolled hypertension with at least one documented SBP≥140 mmHg (in clinic or at home) in the past 12 months; and (v) primary care provided at a participating clinic.\n* Able to speak English\n* Primary care provided at a participating clinic\n\nExclusion Criteria:\n\n* currently pregnant or planning to get pregnant during the study period\n* residence in a long-term care facility, hospice or with a terminal illness with less than 1 year life expectancy as determined by the Primary Care Physician or study team. Stable chronic illness such as compensated cirrhosis, chronic obstructive pulmonary disease, congestive heart failure etc. will not be excluded.\n* estimated Glomerular Filtration Rate (eGFR) \\\u003C30 ml\u002Fmin or on dialysis. Patients with a functioning kidney transplant will not be excluded.\n* inability to provide informed consent or participate in study procedures. For example, conditions that limit ability to participate in phone visits or check BPs in at least one arm.\n* currently participating in another BP management program.\n* plan to move out of the area within the next 12 months.\n* Hispanic ethnicity.","21 Years","85 Years",{"count":119,"type":21},864,[88],"This study will compare two approaches for managing hypertension in Black patients with uncontrolled blood pressure (BP). One approach will include home BP telemonitoring supported by a pharmacist and a community health worker. The other approach will include usual clinic-based care along with a home BP monitor and routine care.",[27],[124,125,126],"high blood pressure","African-American population","remote blood pressure monitoring","2026-05-29",{"date":129,"type":39},"2026-06-02",{"date":131,"type":39},"2024-12-13",{"date":133,"type":21},"2028-09",{"name":135,"class":107},"Wake Forest University Health Sciences",{"id":137,"slug":138,"hasResults":11,"nctId":139,"briefTitle":140,"officialTitle":141,"acronym":142,"eligibilityCriteria":143,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":144,"targetDuration":4,"studyType":22,"phases":146,"briefSummary":147,"conditions":148,"keywords":149,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":153,"startDateStruct":155,"completionDateStruct":157,"leadSponsor":159,"locationsCount":75},"100595383","sequential-multiple-assignment-randomized-trial-to-reduce-food-insecurity-100595383","NCT07031739","Sequential Multiple Assignment Randomized Trial to Reduce Food Insecurity","Sequential Multiple Assignment Randomized Trial to Reduce Food Insecurity and Improve Adherence in Patients With Hypertension","SMART","Inclusion Criteria:\n\n* Must Speak English or Spanish\n* have a diagnosis of Hypertension (HTN)\n* prescribed at least one blood pressure lowering medication (including thiazide diuretic, calcium channel blocker, beta-blocker, angiotensin-converting enzyme inhibitors, or angiotensin receptor blocker)\n* past 2 blood pressures at their primary care doctor were greater than or equal to130\u002F80mmHg (millimeters of Mercury)\n* seen by their primary care doctor in the past 6 months\n* experience Food Insecurities (FI) based on the 2-item Hunger Vital Sign\n\nExclusion Criteria:\n\n* Systolic Blood Pressure \\> 210mmHg or a diastolic blood pressure \\> 120mmHg\n* have a severe cognitive impairment or major psychiatric illness that prevents consent or serious medical condition which either limits life expectancy or requires active management (e.g. certain cancers)\n* pregnant, breastfeeding, or planning to become pregnant in the next 6 months\n* planning on moving out of the area within 6 months\n* lack safe stable housing\n* do not have the ability to store meals\n* lack of a telephone",{"count":145,"type":21},224,[88],"Food insecurity affects 20% of the 116 million people in the US with hypertension and is associated with poor adherence to evidence-based treatments and disparities in hypertension outcomes. Interventions are being used to address food insecurity in clinical care settings, but people differ in the support they need to reduce food insecurity and little is known about which food insecurity interventions work best, or for whom. The goal of this study is to develop and test an adaptive food insecurity intervention using a Sequential Multiple Assignment Randomized Trial to determine which initial food insecurity intervention is more effective in improving adherence and blood pressure in patients with hypertension and for those who do not respond to the initial intervention, evaluate how to best provide additional support.",[27],[150,29,151],"cardiovascular disease","Food insecurity","2026-05-05",{"date":154,"type":39},"2026-05-06",{"date":156,"type":39},"2025-08-18",{"date":158,"type":21},"2030-02",{"name":135,"class":107},{"id":161,"slug":162,"hasResults":11,"nctId":163,"briefTitle":164,"officialTitle":165,"acronym":4,"eligibilityCriteria":166,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":167,"enrollmentInfo":168,"targetDuration":4,"studyType":22,"phases":170,"briefSummary":171,"conditions":172,"keywords":173,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":175,"lastUpdatePostDateStruct":176,"startDateStruct":178,"completionDateStruct":180,"leadSponsor":182,"locationsCount":184},"100599874","phase-2-evaluation-of-efficacy-and-safety-of-iloperidone-for-the-treatment-of-participants-with-uncontrolled-hypertension-100599874","NCT07090161","Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled Hypertension","A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled Hypertension","Inclusion Criteria:\n\n* SiSBP \\>\u002F= 130 mmHg despite \\>8 weeks treatment w\u002F 1 or more antihypertensive therapies\n\nExclusion Criteria:\n\n* Confirmed Grade 3\u002Fsevere hypertension (SiSBP \\>\u002F= 180 mmHg, SiDBP \\>\u002F= 120 mmHg), unstable cardiac disease, renal insufficiency","65 Years",{"count":169,"type":21},240,[24],"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Iloperidone for the Treatment of Participants with Uncontrolled Hypertension",[62,27],[174,29,30],"iloperidone","2026-02-25",{"date":177,"type":39},"2026-02-27",{"date":179,"type":39},"2025-09-15",{"date":181,"type":21},"2026-11",{"name":183,"class":46},"Vanda Pharmaceuticals",28,{"id":186,"slug":187,"hasResults":11,"nctId":188,"briefTitle":189,"officialTitle":190,"acronym":4,"eligibilityCriteria":191,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":192,"targetDuration":4,"studyType":22,"phases":194,"briefSummary":195,"conditions":196,"keywords":197,"overallStatus":208,"whyStopped":4,"lastUpdateSubmitDate":209,"lastUpdatePostDateStruct":210,"startDateStruct":212,"completionDateStruct":214,"leadSponsor":216,"locationsCount":75},"100597635","netrod-pilot-study-of-renal-denervation-with-netrodtm-sixelectrode-radiofrequency-rdn-system-100597635","NCT07061054","Netrod-Pilot Study of Renal Denervation With NetrodTM Sixelectrode Radiofrequency RDN System","Safety and Efficacy of the CE-Marked NetrodTM Renal Denervation System in Treating Patients With Primary Hypertension in the Absence of Anti-hypertensive Medication: a Pilot Study With 20 Subjects","Inclusion criteria:\n\n1. Subject with age ≥18 years or minimum age as required by local regulations and ≤ 70 years old at time of consent\n2. Subject with hypertension who has an office BP of ≥ 150\u002F90 mmHg and \\\u003C 180\u002F110 mmHg (meet both SBP and DBP criteria) at Screening V2, and mean daytime ASBP ≥ 140 mmHg and \\\u003C 170 mmHg by 24-hour ABPM at Screening V2.\n3. Willing and able to provide informed consent\n4. Willing and able to comply with all study-specific visits, assessments, and requirements\n\nExclusion Criteria:\n\n1. 1\\. Subject who is pregnant, nursing or planning to become pregnant during the course of the study\n2. Subject with unilateral or bilateral renal artery that are not suitable for ablation procedure (renal artery stenosis more than 50%, renal aneurysm, renal artery abnormality, renal artery diameter \\\u003C 3 mm or treatable segment length \\\u003C 20 mm)\n3. Subject with single-kidney or history of kidney transplant\n4. Subject with history of renal artery intervention (Percutaneous Transluminal Angioplasty \\[PTA\\] or stenting) or Renal Denervation (RDN)\n5. Subject with any conditions that may affect the accuracy of blood pressure (BP) measurement: such as the diameter of the upper arm is too large for the cuff, or arrhythmia, etc\n6. Subject with known secondary hypertension\n7. Subject with eGFR \\\u003C40 mL\u002Fmin\u002Fl.73m²\n8. Subject with history of hospitalization for hypertensive emergency within past year\n9. Subject with type I diabetes mellitus\n10. Subject with primary pulmonary hypertension\n11. Subject with history of bleeding diathesis and haematological disorders or coagulopathy\n12. Subject with recent history of any embolism within 6 months\n13. Subject with history of coronary artery intervention, unstable angina or myocardial infarction\n14. Subject with stable angina and therefore treated anti-anginal medication (betablockers, calcium antagonists, long-acting nitrates)\n15. Subject with history of abdominal aortic aneurysm\n16. Subject with atrial fibrillation or history of atrial fibrillation in the last 3 years or on rate or rhythm control medication for arrhythmia\n17. Subject with a history of ventricular fibrillation or ventricular tachycardia\n18. Subject known with serum Human Immunodeficiency Virus (HIV)-positive\n19. Subject who is allergic to contrast agents and not responding to preventive medication\n20. Subject with acute or severe systemic infections\n21. Subject with mental illness or any psychological problems that may interfere with participating in the study\n22. Subject with history of stroke or transient ischemic attack (TIA)\n23. Subject with malignant tumors or end-stage disease\n24. Subject with severe Peripheral Artery Disease (PAD) along the access path to renal arteries, including abdominal aneurysm\n25. Subject with severe heart valve stenosis or regurgitation\n26. Subject with heart failure requiring medications (i.e. Angiotensin-Converting Enzyme (ACE)\u002F Angiotensin II Receptor Blockers (ARB), Sodium-Glucose Cotransporter 2 Inhibitors (SGTL2i), diuretics)\n27. Subject with uncontrolled hyperthyroidism or hypothyroidism\n28. Subject with severe electrolyte abnormalities, defined as values above and below the limits of normal (LN) on repeated measurements despite normalization efforts, or with liver function abnormalities, defined as 2 \\> Upper Limit of Normal (ULN)\n29. Subject who requires mechanical ventilation other than Continuous Positive Airway Pressure (CPAP) for sleep apnea\n30. Subject with an implanted pacemaker or Implantable Cardioverter Defibrillator (ICD)\u002F Cardiac Resynchronization Therapy (CRT) device\n31. Subject with a history of major surgery or trauma within 30 days prior to enrolment\n32. Subject who has planned surgery or cardiovascular intervention within the next 12 months\n33. Subject who is participating in other drug or medical device clinical investigations\n34. Subject who is unsuitable to participate in this study in the opinion of investigators (e.g., drug use or alcohol dependency, cognitive impairment, etc.)",{"count":193,"type":21},20,[88],"This single-arm, non-randomized, open-label investigation aims to collect safety and efficacy data of the CE-Marked Netrod™ RDN System in treating European patients with primary hypertension in the absence of anti-hypertensive medication.",[27],[198,199,200,201,202,203,204,205,206,207],"Renal denervation (RDN)","Radiofrequency renal denervation","Sympathetic nervous system","Interventional therapy","Interventional cardiology","Device-based therapy","Renal artery denervation","Blood pressure","Resistant Hypertension","Refractory Hypertension","NOT_YET_RECRUITING","2026-02-09",{"date":211,"type":39},"2026-02-11",{"date":213,"type":21},"2026-04-01",{"date":215,"type":21},"2027-12-01",{"name":217,"class":46},"Shanghai Golden Leaf MedTec Co. Ltd",{"id":219,"slug":220,"hasResults":11,"nctId":221,"briefTitle":222,"officialTitle":223,"acronym":4,"eligibilityCriteria":224,"healthyVolunteers":83,"sex":16,"minAge":17,"maxAge":225,"enrollmentInfo":226,"targetDuration":4,"studyType":22,"phases":228,"briefSummary":230,"conditions":231,"keywords":4,"overallStatus":208,"whyStopped":4,"lastUpdateSubmitDate":232,"lastUpdatePostDateStruct":233,"startDateStruct":235,"completionDateStruct":237,"leadSponsor":239,"locationsCount":4},"100620533","phase-1-a-food-effect-study-of-qls1410-in-healthy-chinese-adults-100620533","NCT07358858","A Food Effect Study of QLS1410 in Healthy Chinese Adults","A Randomized, Open-label, Two-period, Crossover Food Effect Study of QLS1410 in Healthy Chinese Adults","Inclusion Criteria:\n\n1. Able to understand and willing to comply with all study visits, procedures, restrictions and provide the written informed consent form (ICF).\n2. Males and females aged 18 to 55 years, inclusive.\n3. Weight ≥ 50 kg for males and ≥ 45 kg for females, Body mass index (BMI) between 18 and 26 kg\u002Fm\\^2, inclusive, at screening.\n4. Has a mean seated office systolic blood pressure (SBP) 110\\~139 mmHg (inclusive) and diastolic blood pressure (DBP) 70\\~89 mmHg (inclusive) at screening and baseline; measured 3 times consecutively (1-2 min intervals).\n5. QTcF (QT corrected using Fridericia's formula) \\\u003C450 ms for males and \\\u003C470 ms for females.\n6. Participants (including partners) must agree to abstain from sperm\u002Fegg donation and pregnancy plans, and to use highly effective contraception, from signing the ICF until 3 months after receiving the last dose of investigational product.\n\nExclusion Criteria:\n\n1. Any medical condition\u002Fdisease at screening deemed by the investigator to require exclusion, including but not limited to the cardiovascular, respiratory, digestive, urinary, endocrine metabolic, skeletal, muscular, hematologic, immune, nervous system.\n2. Dysphagia or any surgical condition\u002Fdisease that may affect drug absorption, distribution, metabolism, or excretion, at screening.\n3. Use of systemic corticosteroids within 3 months prior to screening.\n4. Any clinically significant abnormal result of vital signs, physical examinations, laboratory tests, chest X-ray, and abdominal B-ultrasound, at screening.\n5. Active viral hepatitis (B or C), TP, and HIV as demonstrated by positive serology at Screening.\n6. Mean pulse \\>100 or \\\u003C50 bpm after ≥5 min of rest at screening (measured 3 times consecutively).\n7. Any of the following laboratory abnormalities at screening: ALT or AST \\>1.5 x upper limit of normal (ULN); Total bilirubin \\>1.5 x ULN (participants with Gilbert's syndrome may qualify if direct bilirubin ≤ULN); Creatinine \\>ULN or eGFR \\\u003C90 mL\u002Fmin\u002F1.73 m²; Serum potassium \\>ULN or sodium \\\u003C135 mmol\u002FL.\n8. Smoking \\>5 cigarettes\u002Fday on average within 6 months before screening, or current use of e-cigarettes.\n9. Alcohol consumption \\>14 units\u002Fweek (1 unit = 357 mL of 3.5% beer, 27 mL of 40% spirits, or 104 mL of 12% wine) within 6 months before screening, or has a positive breath alcohol test at screening.\n10. Blood donation \\>400 mL within 3 months or \\>200 mL within 4 weeks before screening, or plan to donate blood during the study.\n11. Use of strong CYP3A4 or CYP1A2 inhibitors within 7 days or 5 half-lives (whichever is longer) before screening. Use of strong CYP3A4 inducer within 14 days or 5 half-lives (whichever is longer) before screening.\n12. Use of any prescription drugs, OTC drugs, traditional medicines, and dietary supplements within 2 weeks or 5 half-lives (whichever is longer) prior to randomization.\n13. Pregnant\u002Flactating females or positive pregnancy test at screening.\n14. Inability to tolerate a high-fat meal.","55 Years",{"count":227,"type":21},12,[229],"PHASE1","This study is aimed to evaluate the effect of food on pharmacokinetics of QLS1410 in healthy Chinese adults.",[27],"2026-01-15",{"date":234,"type":39},"2026-01-22",{"date":236,"type":21},"2026-01-23",{"date":238,"type":21},"2026-02-07",{"name":240,"class":46},"Qilu Pharmaceutical Co., Ltd.",{"id":242,"slug":243,"hasResults":11,"nctId":244,"briefTitle":245,"officialTitle":245,"acronym":4,"eligibilityCriteria":246,"healthyVolunteers":11,"sex":16,"minAge":116,"maxAge":247,"enrollmentInfo":248,"targetDuration":4,"studyType":22,"phases":250,"briefSummary":251,"conditions":252,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":253,"lastUpdatePostDateStruct":254,"startDateStruct":256,"completionDateStruct":258,"leadSponsor":260,"locationsCount":262},"100593331","renal-pelvic-denervation-pilot-trial-100593331","NCT07005050","Renal Pelvic Denervation Pilot Trial","Inclusion Criteria:\n\n1. Currently taking 2 anti-hypertensive medications (NOTE: no changes to medications allowed until after 2-month primary endpoint).\n\n   \\- As recommended in ACC\u002FAHA 2017 Guideline,2 subjects are to be taking one anti-hypertensive antagonizing the renin-angiotensin system, including ACE inhibitor, ARB or renin inhibitor. Second drug should either be a calcium channel blocker (amlodipine preferred) or a thiazide diuretic.\n2. Stable antihypertensive medical regimen for at least 30 days.\n3. Ambulatory mean daytime SBP ≥135 mmHg.\n4. Ambulatory daytime SBP \\\u003C170 and DBP \\\u003C105 mmHg.\n5. Office systolic SBP ≥140 mmHg and \\\u003C180.\n\nExclusion Criteria:\n\n1. History of non-compliance with medical care or medical treatments.\n2. History of atrial fibrillation.\n3. Pregnant (verified with a urine or blood pregnancy test), breast-feeding, or planning to become pregnant. Note that all premenopausal women will be screened for pregnancy (see section 4.7.4).\n4. Office SBP ≥180 and DBP ≥110 mmHg.\n5. Untreated urinary tract infection.\n6. Renal collecting system is compromised, such that the subject cannot undergo routine cystoscopy and retrograde pyelogram, as exemplified by duplicated collecting system, i.e., two or more ipsilateral ureters.\n7. Pre-existing hydronephrosis, presence of renal calculi or ectopic, pelvic or ptotic kidney(s).\n8. Receiving dialysis treatment.\n9. Renal transplant recipient.\n10. Presence of only one kidney, or patients with dominant unilateral kidney function with one kidney split function less than 35%\n11. Polycystic kidney disease.\n12. Diabetes treated with SGLT2 inhibitor and\u002For GLP-1 agonist\n13. Persistent albuminuria (urine with 30-300 mg albumin\u002Fg creatinine)\n14. Focal sclerosing glomerulosclerosis.\n15. On any of the following medications: clonidine, guanfacine, or methyldopa.\n16. Known secondary causes of hypertension such as adrenal disease, renal artery stenosis, renovascular hypertension.\n17. Evidence in medical history or at screening of hyperaldosteronism, defined as aldosterone\u002Frenin activity \\> 30 or aldosterone level \\>15 ng\u002FdL\n18. Glomerulonephritis or interstitial nephritis or eGFR \\\u003C45 ml\u002Fmin\u002F1.73m2.\n19. Type I diabetes mellitus.\n20. Stenotic valvular heart disease for which reduction of blood pressure would be hazardous.\n21. One or more episodes of orthostatic hypotension within the prior 6 months defined in section 6.6.2 as reduction of systolic blood pressure of ≥20 mmHg or diastolic blood pressure of ≥10 mm Hg within 3 minutes of standing.\n22. Myocardial infarction, unstable angina, or stroke in the prior 6 months.\n23. History of symptomatic heart failure\n24. Echocardiographic evidence of dilated, infiltrative or hypertrophic cardiomyopathy or intracardiac mass.\n25. Surgically correctable valvular heart disease.\n26. Peripheral arterial disease manifest clinically by claudication or non-healing ulcers.\n27. Any medical condition (including psychiatric disease) that would interfere with conducting the study or would not be in the best interest of the subject.\n28. Prior diagnosis of pulmonary hypertension, use of chronic oxygen therapy or need for mechanical ventilation\n29. Presence of severe obstructive sleep apnea not treated adequately by CPAP at screening.\n30. On medications that affect blood pressure through off target effects, e.g., NSAIDs, steroids etc.\n31. Uncorrected bleeding diathesis\n32. Any clinical condition that can affect blood pressure or require the use of medications that can affect blood pressure (e.g., NSAIDs, steroids, cold remedies).\n33. Life expectancy \\\u003C 24 months for any reason (investigator determination).\n34. Works night shifts.\n35. Upper arm circumference \\> 20\".\n36. Subjects currently enrolled in another hypertension trial.\n37. Subjects who previously received device therapy for hypertension, including renal denervation.\n38. Subjects with a history of recurrent renal stones including episodes within the prior 6 months (subjects with first diagnosis of asymptomatic renal stone(s) at baseline\u002Fscreening can be treated and rescreened at least one week following successful therapy of nephrolithiasis).\n39. History of narcotic \u002F opiate drug abuse\n40. History of chronic pain syndrome receiving ongoing therapy with narcotic and\u002For opiate therapy\n41. Active uroepithelial cancer\n42. Artificial urinary sphincter or penile prosthesis implanted.\n43. Planned medical procedures that could potentially interfere with measurement of blood pressure or assessment of any safety\u002Feffectiveness endpoints within 12 months of randomization\n44. Conditions that could potentially interfere with accuracy of blood pressure measurements\n45. Vulnerable subject populations (e.g., incarcerated or cognitively challenged adults).\n46. Pre-existing urological abnormalities such as hydronephrosis, ureteral vesicular reflux (congenital or acquired), neoplasia, etc.\n47. Urinary tract anomalies or primary (FSGS) or secondary (e.g., Diabetic nephropathy) renal disease","80 Years",{"count":249,"type":21},60,[88],"The RPD Pilot trial will evaluate the safety and effectiveness of Verve Medical's RPDTM renal denervation system for hypertensive patients with uncontrolled blood pressure despite use of two medications at a therapeutic dose.\n\nThe novelty of the RPDTM system relates to its placement via natural orifice into the renal pelvis (bilaterally) for delivery of radiofrequency energy to ablate the nerves that pass through the outer wall of the renal pelvis, a technique referred to as renal pelvic denervation (RPD).",[27],"2026-01-07",{"date":255,"type":39},"2026-01-08",{"date":257,"type":21},"2025-12-30",{"date":259,"type":21},"2029-03-02",{"name":261,"class":46},"Verve Medical, Inc",5,{"id":264,"slug":265,"hasResults":11,"nctId":266,"briefTitle":267,"officialTitle":268,"acronym":269,"eligibilityCriteria":270,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":271,"targetDuration":4,"studyType":22,"phases":273,"briefSummary":275,"conditions":276,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":278,"lastUpdatePostDateStruct":279,"startDateStruct":281,"completionDateStruct":283,"leadSponsor":285,"locationsCount":287},"100495555","phase-3-intensification-of-blood-pressure-lowering-therapeutics-based-on-diuretics-versus-usual-management-for-uncontrolled-hypertension-in-patients-with-moderate-to-severe-chronic-kidney-disease-100495555","NCT05732727","Intensification of Blood Pressure Lowering Therapeutics Based on Diuretics Versus Usual Management for Uncontrolled Hypertension IN Patients With Moderate to Severe Chronic Kidney Disease","Intensification of Blood Pressure Lowering Therapeutics Based on Diuretics Versus Usual Management for Uncontrolled Hypertension IN Patients With Moderate to Severe Chronic Kidney Disease: an Open Label, a Cluster Randomized Controlled, Phase 3 Trial","THINK","Inclusion Criteria:\n\n* Male or female \\>=18 years with a clinical frailty score ≤5 for patient aged over 80\n* Advanced or moderate chronic kidney disease (eGFR 15 to 44.9 mL\u002Fmin\u002F1.73m² using CKD-EPI formula)\n* Arterial hypertension treated with at least one blood pressure lowering drug therapy among blockers of the renin-angiotensin system (ACEi or ARB), at the maximal posology tolerated by the patients stable since at least one month. Other blood pressure lowering drug therapies are tolerated in combination with or in the event of intolerance to ACE inhibitors or ARBs.\n* Uncontrolled office BP\n* Uncontrolled office BP (\\>140 and\u002For 90 mmHg) confirmed by home blood pressure monitoring (\\>135 and\u002For 85 mmHg) or Day-time Ambulatory Blood Pressure Monitoring\n* Participant covered by or entitled to social security\n* Written informed consent obtained from the participant\n\nExclusion Criteria:\n\n* Patient following any measures of legal presentation\n* Pregnant or breastfeeding woman\n* woman of childbearing without a highly effective contraceptive measure (combined or progestogen-only hormonal contraception associated with inhibition of ovulation, intrauterine device or intrauterine hormone-releasing system)\n* Clinical signs of hypovolemia\n* Symptomatic orthostatic hypotension\n* Hyponatremia (\\\u003C130 mmol\u002FL)\n* Dyskalemia (\\\u003C3,5 mmol\u002FL or \\>5,5 mmol\u002FL)\n* Major adverse cardiovascular event during the last three months: myocardial infarction, heart failure hospitalization, stroke\n* Current medical history of cancer requiring chemotherapy\n* Solid organ transplantation\n* Two or more diuretic agents (loop diuretic, thiazides and thiazide-like diuretics)\n* Mineralocorticoid receptor antagonists\n* Autosomal dominant polycystic kidney disease treated with Tolvaptan\n* Contraindication to diuretics involved in the algorithm\n* Severe heart failure (NYHA III\\_IV)\n* Cirrhosis Child B-C",{"count":272,"type":21},720,[274],"PHASE3","Chronic kidney disease (CKD) is a major public health issue worldwide. Hypertension is the first risk factor in patients with CKD for mortality, cardiovascular disease and end-stage renal disease. It's now well established that lowering blood pressure (BP) reduces renal and cardiovascular complications in this high-risk population. In the general population, in addition to lifestyle interventions, the strategy to initiate and escalate a BP-lowering drug treatment is well described. The drug therapies recommended to achieve optimal BP control in the general population are the following: blockers of the renin-angiotensin system (angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB)), diuretics (thiazides and thiazide-like diuretics), and calcium channel blockers. For patients with CKD, the guidelines advise to start the BP-lowering agent with ACEi or ARB, but then, there is no strong evidence to support the preferential use of any particular agent in controlling BP and the results of clinical trials are discordant. In the NephroTest cohort, a French cohort of patients with CKD stage 1 to 5, among 2015 patients, 1782 had hypertension, only 54% had a diuretic and 44% had uncontrolled hypertension. In this cohort, extracellular fluid (ECF) overload was an independent determinant of hypertension, uncontrolled hypertension and apparent treatment resistant hypertension. In the same cohort, ECF overload was independently associated with end-stage kidney disease and death. Our hypothesis is that patients with CKD and uncontrolled hypertension are fluid overloaded and that the second line of treatment after an ACEi or an ARB should be a diuretic. We hypothesize that a specific algorithm to lower BP in patients with moderate to severe CKD based on diuretics will be more effective in term of cardiovascular event, mortality and evolution to end-stage kidney disease as compared to standard of care.",[277,27],"Chronic Kidney Disease(CKD)","2025-11-27",{"date":280,"type":39},"2025-12-01",{"date":282,"type":39},"2023-03-28",{"date":284,"type":21},"2029-03",{"name":286,"class":107},"University Hospital, Tours",40,{"id":289,"slug":290,"hasResults":11,"nctId":291,"briefTitle":292,"officialTitle":293,"acronym":4,"eligibilityCriteria":294,"healthyVolunteers":83,"sex":16,"minAge":17,"maxAge":167,"enrollmentInfo":295,"targetDuration":4,"studyType":22,"phases":297,"briefSummary":298,"conditions":299,"keywords":4,"overallStatus":208,"whyStopped":4,"lastUpdateSubmitDate":300,"lastUpdatePostDateStruct":301,"startDateStruct":303,"completionDateStruct":305,"leadSponsor":307,"locationsCount":75},"100604663","phase-1-a-phase-i-trial-of-qls1410-in-healthy-chinese-adults-and-participants-with-mild-essential-hypertension-100604663","NCT07152444","A Phase I Trial of QLS1410 in Healthy Chinese Adults and Participants With Mild Essential Hypertension","A Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Food Effect of Single and Multiple Ascending Doses of QLS1410 in Healthy Chinese Adults and Participants With Mild Essential Hypertension","Inclusion Criteria:\n\n* Part A \\& Part B: Healthy Participants\n* Able to understand and willing to comply with all study visits, procedures, restrictions and provide the written informed consent form (ICF).\n* Males and females aged 18 to 55 years, inclusive.\n* Weight ≥ 50 kg for males and ≥ 45 kg for females, Body mass index (BMI) between 18 and 26 kg\u002Fm\\^2, inclusive, at screening.\n* Has a mean seated office systolic blood pressure (SBP) 110\\~139 mmHg (inclusive) and diastolic blood pressure (DBP) 70\\~89 mmHg (inclusive) at screening and baseline; measured 3 times consecutively (1-2 min intervals).\n* QTcF (QT corrected using Fridericia's formula) \\\u003C450 ms for males and \\\u003C470 ms for females.\n* Participants (including partners) must agree to abstain from sperm\u002Fegg donation and pregnancy plans, and to use highly effective contraception, from signing the ICF until 3 months after receiving the last dose of investigational product.\n* Part C: Participants with Mild Essential Hypertension\n* Able to understand and willing to comply with all study visits, procedures, restrictions and provide the ICF.\n* Males and females aged 18 to 65 years (18 to 65 years in MAD study), inclusive.\n* Weight ≥ 50 kg for males and ≥ 45 kg for females, BMI between 18 and 28 kg\u002Fm\\^2, inclusive, at screening.\n* Has a mean seated office SBP 140\\~159 mmHg (inclusive) and DBP 85\\~99 mmHg (inclusive) at screening and baseline; measured 3 times consecutively (1-2 min intervals).\n* QTcF \\\u003C450 ms for males and \\\u003C470 ms for females.\n* No use of antihypertensive medications (including ACEIs, ARBs, CCBs, ARNIs, diuretics, etc.) within 30 days prior to signing the ICF.\n* Participants (including partners) must agree to abstain from sperm\u002Fegg donation and pregnancy plans, and to use highly effective contraception, from signing the ICF until 3 months after receiving the last dose of investigational product.\n\nExclusion Criteria:\n\n* Part A \\& Part B: Healthy Participants\n* Any medical condition\u002Fdisease at screening deemed by the investigator to require exclusion, including but not limited to the nervous, psychiatric, cardiovascular, hematologic\u002Flymphatic, immune, respiratory, digestive, urinary, metabolic and skeletal systems.\n* Dysphagia or any surgical condition\u002Fdisease that may affect drug absorption, distribution, metabolism, or excretion, at screening.\n* Use of systemic corticosteroids within 3 months prior to screening.\n* Mean pulse\u002Fheart rate (HR) \\>100 or \\\u003C50 bpm after ≥5 min of rest at screening (measured 3 times consecutively).\n* Any laboratory abnormalities that meet the test requirements should be noted during screening (if necessary, retest can be conducted at least one week apart):\n* Smoking \\>5 cigarettes\u002Fday on average within 6 months before screening, or current use of e-cigarettes.\n* Alcohol consumption \\>14 units\u002Fweek (1 unit = 360 mL of beer, 45 mL of 40% spirits, or 150 mL of wine) within 6 months before screening, or has a positive breath alcohol test at screening.\n* Blood donation \\>400 mL within 3 months or \\>200 mL within 4 weeks before screening, or plan to donate blood during the study.\n* Use of strong CYP3A4 or CYP1A2 inhibitors within 7 days or 5 half-lives (whichever is longer) before screening. Use of strong CYP3A4 inducer within 14 days or 5 half-lives (whichever is longer) before screening.\n* Use of any prescription drugs, OTC drugs, traditional medicines, and dietary supplements within 2 weeks or 5 half-lives (whichever is longer) prior to randomization.\n* Pregnant\u002Flactating females or positive pregnancy test at screening.\n* Inability to tolerate a high-fat meal (for Part B only).\n\nPart C: Participants with Mild Essential Hypertension\n\n* Secondary hypertension.\n* Orthostatic tachycardia or hypotension at screening, or history of related symptoms (e.g., dizziness, weakness, blurred vision upon standing).\n* History of syncope.\n* Metabolic\u002Fcardiovascular disorders: 1) Diabetes (fasting glucose ≥7.0 mmol\u002FL \\[126 mg\u002FdL\\] or HbA1c ≥6.5%); 2) History of cardiovascular events (e.g., stroke, transient ischemic attack, myocardial infarction, unstable angina, coronary artery bypass grafting, percutaneous coronary intervention, heart failure hospitalization) or clinically significant valvular disease; 3) Personal\u002Ffamily history of long QT syndrome, torsades de pointes (TdP), arrhythmias, or sudden cardiac death; 4) Other conditions that may interfere with the study or increase risk, per investigator judgment.\n* Laboratory abnormalities (as defined in Part A\u002FB, with repeat testing allowed).\n* Any other condition deemed unsuitable by the investigator.",{"count":296,"type":21},78,[229],"The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and food effect of single and multiple ascending doses of QLS1410 in healthy Chinese adults and participants with mild essential hypertension",[27],"2025-08-26",{"date":302,"type":39},"2025-09-03",{"date":304,"type":21},"2025-09",{"date":306,"type":21},"2026-07",{"name":240,"class":46},{"id":309,"slug":310,"hasResults":11,"nctId":311,"briefTitle":312,"officialTitle":313,"acronym":4,"eligibilityCriteria":314,"healthyVolunteers":83,"sex":16,"minAge":17,"maxAge":167,"enrollmentInfo":315,"targetDuration":4,"studyType":22,"phases":317,"briefSummary":318,"conditions":319,"keywords":320,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":325,"lastUpdatePostDateStruct":326,"startDateStruct":328,"completionDateStruct":330,"leadSponsor":332,"locationsCount":75},"100596909","phase-1-sal0140-safety-tolerability-pharmacokinetic-and-pharmacodynamic-study-in-a-healthy-chinese-population-100596909","NCT07051603","SAL0140 Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in a Healthy Chinese Population","A Phase 1, Randomized, Double-Blind Placebo-Controlled Single and Multiple Dose Study Plus Food Effect Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of SAL0140 in Healthy Chinese Subjects","Inclusion Criteria:\n\n* Subjects has fully understood and voluntarily signed the informed consent form, and is able to comply with the requirements and restrictions listed in the informed consent form;\n* Male or female aged 18-65 years (including 18 and 65 years old);\n* Male body weight ≥50kg, female body weight ≥45kg and body mass index (BMI) between 19.0 - 26.0 kg\u002Fm2 (including 19.0 and 26.0, BMI = weight(kg) \u002F height(cm)2) at screening;\n* All examinations (including physical examination, vital signs, laboratory tests, ECG, chest X-ray (anterior and lateral views), etc.) show no abnormalities or minor abnormalities deemed non clinical signiant by the investigator;\n\nExclusion Criteria:\n\n* Subjects with orthostatic tachycardia or orthostatic hypotension at screening; or those with a history of orthostatic hypotension symptoms (such as dizziness, fatigue, blurred vision, pallor upon standing) or orthostatic tachycardia symptoms (such as dizziness, palpitations, tremors, general weakness, blurred vision, exercise intolerance when standing);\n* Subjects have used corticosteroids within 3 months prior to dosing;\n* Subjects with personal or family history of long QT syndrome, torsades de pointes, or other complex arrhythmias, or family history of sudden death;\n* Subjects with prolonged QTcF interval (\\>450msec) on ECG;\n* Subjects with potassium levels above the upper limit of normal (\\>ULN) or sodium levels below the lower limit of normal (\\\u003CLLN) in biochemistry tests;\n* Subjects with known allergies to excipients in the study drug or history of severe allergic reactions (including food, drugs, insect bites, etc.);\n* Subjects with any disease history or current condition that may affect the safety evaluation or drug disposition of the study participant, including but not limited to central nervous system, cardiovascular system, digestive system, respiratory system, urinary system, blood system, immune system, psychiatric conditions, metabolic disorders, gastrointestinal surgery (except appendectomy), etc.;\n* Subjects have undergone gastric surgery, vagotomy, bowel resection, or any surgery that may interfere with gastrointestinal motility, pH, or absorption;\n* Subjects received live or attenuated vaccines within 4 weeks prior to screening;\n* Subjects consume excessive tea, coffee, and\u002For caffeinated beverages (more than 8 cups, 1 cup = 250 mL) daily, or have consumed these beverages within 48h prior to dosing, or cannot stop consuming during the trial;\n* Subjects have taken any prescription drugs, over-the-counter medications, Chinese herbs, or dietary supplements (including vitamins, health foods, etc.) within 14 days prior to dosing;\n* Subjects with a history of long-term consumption of xanthine-rich or grapefruit-containing beverages or foods, or who have consumed any xanthine-rich or grapefruit products within 48h prior to dosing;\n* Subjects have smoked within 3 months prior to screening, or cannot stop using any tobacco products during the trial;\n* Subjects have participated in other clinical trials and taken any investigational drugs within 3 months prior to screening;\n* Subjects have donated blood or lost blood ≥400 mL, received blood transfusion or blood products within 3 months prior to screening;\n* Subjects have had unprotected sexual intercourse within 2 weeks prior to screening; study participants and their spouses or partners who have pregnancy plans, sperm\u002Fegg donation plans during the study period until 1 month after dosing, or do not agree to use at least one of the following acceptable effective contraception methods:\n\n  * Correctly placed intrauterine device;\n  * Male\u002Ffemale condom used in combination with topical spermicide (i.e., foam, gel, film, cream, or suppository);\n  * Male vasectomy or vas deferens ligation;\n  * Female bilateral tubal ligation\u002Fbilateral salpingectomy or bilateral tubal occlusion surgery (occlusion surgery verified effective by relevant instruments);\n  * Abstinence.\n* Pregnant or lactating women, or women of childbearing potential with positive pregnancy screening results;\n* Subjects are alcoholic or regular drinkers within 3 months prior to screening, i.e., weekly alcohol consumption exceeding 14 standard units (1 unit = 360 mL beer or 45 mL spirits with 40% alcohol content or 150 mL wine) or positive baseline alcohol breath test, or cannot stop using any alcohol-containing products during the trial;\n* Subjects positive drug abuse screening or history of drug abuse or previous use of illicit drugs;\n* Subjects tested positive for hepatitis B surface antigen, hepatitis C antibody, syphilis antibody, or human immunodeficiency virus (HIV) antibody; Subjects deemed by the investigator to have poor compliance or other factors that unsuitable for participation in this trial.",{"count":316,"type":21},82,[229],"The purpose of this study is to evaluate the safety, tolerability pharmacokinetics and pharmacodynamics of SAL0140 healthy Chinese population.",[27],[321,322,323,324],"SAL0140","Uncontrolled hypertension","Pharmacokinetic","Pharmacodynamic","2025-07-03",{"date":327,"type":39},"2025-07-04",{"date":329,"type":39},"2025-06-09",{"date":331,"type":21},"2026-02",{"name":74,"class":46},{"id":334,"slug":335,"hasResults":11,"nctId":336,"briefTitle":337,"officialTitle":338,"acronym":339,"eligibilityCriteria":340,"healthyVolunteers":11,"sex":16,"minAge":116,"maxAge":247,"enrollmentInfo":341,"targetDuration":4,"studyType":22,"phases":342,"briefSummary":343,"conditions":344,"keywords":346,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":349,"lastUpdatePostDateStruct":350,"startDateStruct":352,"completionDateStruct":354,"leadSponsor":356,"locationsCount":75},"100588225","addressing-medication-non-adherence-in-patients-with-poorly-controlled-hypertension-using-urine-mass-spectrometry-100588225","NCT06938633","Addressing Medication Non-adherence in Patients With Poorly Controlled Hypertension Using Urine Mass Spectrometry","Utility of Urine Mass Spectrometry Analysis in Addressing Medication Non-adherence in Patients With Poorly Controlled Hypertension","ADURINE","Inclusion Criteria:\n\n1. Age of 21 - 80 years\n2. Systolic blood pressure of ≥140 mmHg or average systolic blood pressure ≥135 mmHg, or diastolic blood pressure ≥90 mmHg or average diastolic blood pressure ≥85 mmHg, on at least two measurements\n3. Currently taking 2 or more hypertension medications\n4. Able to provide informed consent.\n\nExclusion Criteria:\n\n* Significant kidney impairment with eGFR of less than 45mL\u002Fmin\u002F1.73m2 or on dialysis\n* Known history of chronic liver disease",{"count":86,"type":21},[88],"* Hypertension is the single largest contributor to cardiovascular disease and death. While adequate control of hypertension reduces risk of disease, many patients have uncontrolled hypertension. This is often due to medication non-adherence. Left undetected, patients are prescribed additional medications, and referred to multiple specialists for investigations - leading to increased healthcare costs. Hence, detecting non-adherence to antihypertensive medications is important. However, patient history, patient recall, or questionnaires, are often inaccurate. Most recently, urine measurements of antihypertensive drug levels, using mass spectrometry, has been established as the gold standard to assess medication adherence. The one-time urine test for medication adherence is ideal: It's convenient, non-invasive, economical, and can be easily performed in a clinic setting. By improving blood pressure control, this will lead to reductions in healthcare visits, avoidance of catastrophic cardiovascular events. Ultimately, this translates to significant economic savings for both patients with hypertension and the healthcare system.\n* Therefore, the investigators hypothesize that the implementation of urine adherence testing coupled with targeted counselling will improve the adherence and blood pressure control in hypertension. To do this, the investigators aim to (1) evaluate for medication adherence in 312 participants with recent stroke and hypertension; (2) evaluate for medication non-adherence in participants with uncontrolled hypertension; and (3) assess if detection of non-adherence can improve hypertension control.",[62,27,345],"Non-Adherence, Medication",[347,322,348],"Urine mass spectrometry","Medication non-adherence","2025-04-14",{"date":351,"type":39},"2025-04-22",{"date":353,"type":39},"2024-02-07",{"date":355,"type":21},"2025-09-30",{"name":357,"class":107},"Changi General Hospital",{"id":359,"slug":360,"hasResults":11,"nctId":361,"briefTitle":362,"officialTitle":363,"acronym":364,"eligibilityCriteria":365,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":366,"targetDuration":4,"studyType":368,"phases":4,"briefSummary":369,"conditions":370,"keywords":372,"overallStatus":208,"whyStopped":4,"lastUpdateSubmitDate":375,"lastUpdatePostDateStruct":376,"startDateStruct":378,"completionDateStruct":380,"leadSponsor":382,"locationsCount":75},"100576085","smart-study-in-real-world-100576085","NCT06780696","SMART Study in Real World","Sympathetic Mapping and Ablation of Renal Nerves to Treat Uncontrolled Hypertension in Real World","SMART-RW","1. \\*\\*Inclusion Criteria (for A. Prospective Cohort)\\*\\*\n\n   * Patients are ≥18 years old;\n   * Patients with drug-resistant hypertension patients who are intolerant to drug therapy and, in either case, need to reduce medications;\n   * Patients consent to receive msRDN treatment using the commercially available msRDN system by SyMap Medical (Suzhou), Ltd and to fulfill follow-up requirements.\n2. \\*\\*Exclusion Criteria (for A. Prospective Cohort)\\*\\*\n\n   * Subjects are withdrawn from the study due to various reasons;\n   * Investigators, ethics committees or regulatory agencies may halt or terminate the study due to medical perspectives or ethical considerations.\n3. \\*\\*Inclusion Criteria (for B. Retrospective Cohort)\\*\\*\n\n   * Patients are ≥18 years old;\n   * Patients with drug-resistant hypertension patients who are intolerant to drug therapy and, in either case, need to reduce medications;\n   * Patients who have been received msRDN procedure using commercially available msRDN system by SyMap Medical (Suzhou), Ltd;\n4. \\*\\*Exclusion Criteria (for B. Retrospective Cohort) \\*\\*\n\n   * Subjects are withdrawn from the study due to various reasons;\n   * Investigators, ethics committees or regulatory agencies may halt or terminate the study due to medical perspectives or ethical considerations.",{"count":367,"type":21},1000,"OBSERVATIONAL","This study is a multicenter, single-arm, open-label and post-market study in a real world patient population with uncontrolled hypertension to document the long-term safety and efficacy of a renal mapping\u002Fselective renal denervation (msRDN) system (SyMap Medical (Suzhou), Ltd, Suzhou, China) and conducted in accordance with the requirements by National Medical Production Administration (NMPA) of China. The msRDN system consists of a disposable renal artery radiofrequency ablation catheter (Registration No: National Medical Device Approval 20243011383), a console with both electronic stimulation and radiofrequency ablation function (Registration No: National Medical Device Approval 20243011384). The study includes prospective cohort and retrospective cohort.\n\nApproximately1,000 patients with uncontrolled hypertension who undergo msRDN procedure will be recruited from over 30 centers in China. Subjects enrolled in the study will be followed for at least three years after msRDN procedure. This study includes patients with drug-resistant hypertension or patients who are intolerant to drug therapy and, in either case, need to reduce antihypertensive medications per the inclusion criteria defined in the protocol.",[62,27,206,371],"Reduce Antihypertensive Drug Burden",[30,29,373,374],"reduce antihypertensive medications","resistant hypertension","2025-02-13",{"date":377,"type":39},"2025-02-17",{"date":379,"type":21},"2025-02",{"date":381,"type":21},"2029-04",{"name":383,"class":46},"SyMap Medical (Suzhou), Ltd."]